Efficacy and safety of perioperative, neoadjuvant, or adjuvant immunotherapy alone or in combination with chemotherapy in early-stage non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials.

Ther Adv Med Oncol · 2024 · PMC11457281 · PMID 39376583

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Within the 2 adjuvant RCTs, the adjuvant ICI group demonstrated a significant benefit in DFS (HR = 0.78, 95% CI: 0.69–0.90) and a nonsignificant trend toward improved OS (HR = 0.94, 95% CI: 0.78–1.12) compared to the control group ( Figure 2(b) and ( c )).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.